Astrazeneca, Bristol-Myers Squibb Release Statement to American Diabetes Association

Earlier this week, the American Diabetes Association called for manufacturers of incretin-based therapies to make patient-level data available from clinical trials for an independent analysis of pancreatic safety. AstraZeneca

and Bristol-Myers Squibb Company

are pleased to see the American Diabetes Association's engagement and efforts to facilitate further understanding of this topic. AstraZeneca and Bristol-Myers Squibb have been and will continue to work with health authorities and scientific experts around the world to closely monitor the use of our GLP-1 receptor agonist and DPP-4 inhibitor through comprehensive surveillance programs to ensure patients and physicians have a clear understanding of the risk/benefit profile of these medications. AstraZeneca and Bristol-Myers Squibb recognize there can be value in pooling patient level data from trials of agents in a class for the purpose of an independent meta-analysis of safety sponsored by the American Diabetes Association. We support the American Diabetes Association's initiative to make scientifically valid results of a pooled analysis of safety data available to the public and scientific communities through an independent review, and look forward to a discussion with the American Diabetes Association about the logistics of its proposal. AstraZeneca and Bristol-Myers Squibb have an unwavering commitment to patient safety and the appropriate use of our medicines. We are committed to communicating accurate and meaningful information about our sponsored clinical trials in a timely, accurate, balanced and complete manner, regardless of outcome and with respect for patient confidentiality. AstraZeneca/Bristol-Myers Squibb Diabetes Alliance Dedicated to addressing the global burden of diabetes by advancing individualized patient care, AstraZeneca and Bristol-Myers Squibb are working in collaboration to research, develop and commercialize a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control. Find out more about the Alliance and our commitment to meeting the needs of health care professionals and people with diabetes at www.astrazeneca.com or www.bms.com.